Literature DB >> 1580456

A new drug (566C80) for the treatment of Pneumocystis carinii pneumonia.

W T Hughes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1580456     DOI： 10.7326/0003-4819-116-11-953

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  3 in total

1.  Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis.

Authors:  H W Murray; J Hariprashad
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 2.  Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia.

Authors:  H F Vöhringer; K Arastéh
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

3.  Antipneumocystis activity of 17C91, a prodrug of atovaquone.

Authors:  J C Comley; C L Yeates; T J Frend
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.